{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:23:08Z","timestamp":1786112588696,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00393-026-01846-w","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:32:40Z","timestamp":1785328360000},"page":"430-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Von CAR-T zu T-cell-Engager","From CAR-T to T-cell engagers"],"prefix":"10.1007","volume":"85","author":[{"given":"Matthias","family":"Pierer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"1846_CR1","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett\u00a0G, Mackensen\u00a0A, Mougiakakos\u00a0D (2023) CAR T\u2011cell therapy in autoimmune diseases. Lancet 402:2034\u20132044","journal-title":"Lancet"},{"key":"1846_CR2","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth\u00a0J et\u00a0al (2025) CD19-targeting CAR T\u2011cell therapy in patients with diffuse systemic sclerosis: a\u00a0case series. Lancet Rheumatol 7:e83\u2013e93","journal-title":"Lancet Rheumatol"},{"key":"1846_CR3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur\u00a0C et\u00a0al (2025) Effects of different B\u2011cell-depleting strategies on the lymphatic tissue. Ann Rheum Dis 84:2065\u20132074","journal-title":"Ann Rheum Dis"},{"key":"1846_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","volume":"32","author":"F M\u00fcller","year":"2026","unstructured":"M\u00fcller\u00a0F, Hagen\u00a0M, Wirsching\u00a0A et\u00a0al (2026) CD19 CAR\u2011T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial. Nat Med 32:1142\u20131151. https:\/\/doi.org\/10.1038\/s41591-025-04185-6","journal-title":"Nat Med"},{"key":"1846_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F et\u00a0al (2024) CD19 CAR T\u2011cell therapy in autoimmune disease: a\u00a0case series with follow-up. N Engl J Med 390:687\u2013700","journal-title":"N Engl J Med"},{"key":"1846_CR6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia\u00a0A et\u00a0al (2024) Clinical efficacy and autoantibody seroconversion with CD19-CAR T\u2011cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis 83:1597\u20131598","journal-title":"Ann Rheum Dis"},{"key":"1846_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann\u00a0C et\u00a0al (2023) Treatment of a\u00a0patient with severe systemic sclerosis using CD19-targeted CAR T\u00a0cells. Ann Rheum Dis 82:1117\u20131120","journal-title":"Ann Rheum Dis"},{"key":"1846_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos\u00a0D et\u00a0al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385:567\u2013569","journal-title":"N Engl J Med"},{"key":"1846_CR9","unstructured":"Albach FN, et\u00a0al. Rapid and profound treatment response of difficult-to-treat rheumatoid arthritis to CD19 CAR T\u2011cell therapy. EULAR Rheumatology Open."},{"key":"1846_CR10","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","volume":"84","author":"I Minopoulou","year":"2025","unstructured":"Minopoulou\u00a0I et\u00a0al (2025) Anti-CD19 CAR T\u2011cell therapy induces antibody seroconversion and complete B\u2011cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann Rheum Dis 84:e4\u2013e7","journal-title":"Ann Rheum Dis"},{"key":"1846_CR11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ard.2025.04.029","volume":"84","author":"L Uhlmann","year":"2025","unstructured":"Uhlmann\u00a0L et\u00a0al (2025) Effective use of anti-CD19 chimeric antigen receptor T cells in a case of treatment-resistant granulomatosis with polyangiitis. Ann Rheum Dis 84:1280\u20131283","journal-title":"Ann Rheum Dis"},{"key":"1846_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt\u00a0W et\u00a0al (2024) Third-generation CD19 CAR\u2011T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 83:543","journal-title":"Ann Rheum Dis"},{"key":"1846_CR13","unstructured":"Pecher AC, et\u00a0al. CD19-targeting CAR T\u2011cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation. EULAR Rheumatology Open."},{"key":"1846_CR14","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen\u00a0A et\u00a0al (2022) Anti-CD19 CAR T\u2011cell therapy for refractory systemic lupus erythematosus. Nat Med 28:2124\u20132132","journal-title":"Nat Med"},{"key":"1846_CR15","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno\u00a0JN, Maus\u00a0MV, Hinrichs\u00a0CS (2024) CAR T cells and T\u2011cell therapies for cancer: a translational science review. JAMA 332:1924\u20131935","journal-title":"JAMA"},{"key":"1846_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett\u00a0G et\u00a0al (2024) Advancements and challenges in CAR T\u2011cell therapy in autoimmune diseases. Nat Rev Rheumatol 20:531\u2013544","journal-title":"Nat Rev Rheumatol"},{"key":"1846_CR17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/ard-2024-225727","volume":"83","author":"G Schett","year":"2024","unstructured":"Schett\u00a0G, Nagy\u00a0G, Kr\u00f6nke\u00a0G, Mielenz\u00a0D (2024) B\u2011cell depletion in autoimmune diseases. Ann Rheum Dis 83:1409\u20131420","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 5","key":"1846_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/ar3909","volume":"14","author":"HE Mei","year":"2012","unstructured":"Mei\u00a0HE, Schmidt\u00a0S, D\u00f6rner\u00a0T (2012) Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther 14(Suppl 5):S1. https:\/\/doi.org\/10.1186\/ar3909","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1846_CR19","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova\u00a0G, Mraz\u00a0M (2020) The regulation and function of CD20: an \u201cenigma\u201d of B\u2011cell biology and targeted therapy. Haematologica 105(6):1494\u20131506. https:\/\/doi.org\/10.3324\/haematol.2019.243543","journal-title":"Haematologica"},{"issue":"1","key":"1846_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor\u00a0BP, Raman\u00a0VS, Erickson\u00a0LD et\u00a0al (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J\u00a0Exp Med 199(1):91\u201398. https:\/\/doi.org\/10.1084\/jem.20031330","journal-title":"J Exp Med"},{"key":"1846_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah\u00a0N, Chari\u00a0A, Scott\u00a0E, Mezzi\u00a0K, Usmani\u00a0SZ (2020) B\u2011cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34:985\u20131005. https:\/\/doi.org\/10.1038\/s41375-020-0734-z","journal-title":"Leukemia"},{"key":"1846_CR22","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang\u00a0W, He\u00a0S, Zhang\u00a0W et\u00a0al (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83:1304\u20131314. https:\/\/doi.org\/10.1136\/ard-2024-225785","journal-title":"Ann Rheum Dis"},{"key":"1846_CR23","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller\u00a0F, Wirsching\u00a0A, Hagen\u00a0M et\u00a0al (2025) BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med 31:1793\u20131797. https:\/\/doi.org\/10.1038\/s41591-025-03718-3","journal-title":"Nat Med"},{"key":"1846_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit\u00a0V, Benatar\u00a0M, Kurtoglu\u00a0M et\u00a0al (2023) Safety and clinical activity of autologous RNA chimeric antigen receptor T\u2011cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol 22:578\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(23)00194-1","journal-title":"Lancet Neurol"},{"key":"1846_CR25","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","volume":"32","author":"T Vu","year":"2026","unstructured":"Vu\u00a0T, Durmus\u00a0H, Rivner\u00a0M et\u00a0al (2026) BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 32:1131\u20131141. https:\/\/doi.org\/10.1038\/s41591-025-04171-y","journal-title":"Nat Med"},{"key":"1846_CR26","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41591-025-04170-z","volume":"32","author":"RR Fedak","year":"2026","unstructured":"Fedak\u00a0RR, Ruggerie\u00a0RN, Shan\u00a0Y et\u00a0al (2026) BCMA-directed mRNA CAR\u2011T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial. Nat Med 32:1118\u20131130. https:\/\/doi.org\/10.1038\/s41591-025-04170-z","journal-title":"Nat Med"},{"key":"1846_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ard.2025.05.007","volume":"84","author":"HM Lorenz","year":"2025","unstructured":"Lorenz\u00a0HM, Merkt\u00a0W, Brandt\u00a0J, Giese\u00a0T, Exner\u00a0T, Blank\u00a0N et\u00a0al (2025) One-year remission of therapy-resistant SLE after a single course with the bispecific CD3:BCMA antibody teclistamab, but induction of a non-infectious Crohn\u2019s-like inflammatory bowel disease. Ann Rheum Dis 84:1277\u20131279. https:\/\/doi.org\/10.1016\/j.ard.2025.05.007","journal-title":"Ann Rheum Dis"},{"key":"1846_CR28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander\u00a0T, Kr\u00f6nke\u00a0J, Cheng\u00a0Q, Keller\u00a0U, Kr\u00f6nke\u00a0G (2024) Teclistamab-induced remission in refractory systemic lupus erythematosus. N Engl J Med 391:864\u2013866","journal-title":"N Engl J Med"},{"key":"1846_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen\u00a0M et\u00a0al (2024) BCMA-targeted T\u2011cell-engager therapy for autoimmune disease. N Engl J Med 391:867\u2013869. https:\/\/doi.org\/10.1056\/NEJMc2408786","journal-title":"N Engl J Med"},{"key":"1846_CR30","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","volume":"32","author":"C D\u00fcsing","year":"2026","unstructured":"D\u00fcsing\u00a0C, Gy\u00f6rfi\u00a0AH, St\u00fctz\u00a0AN et\u00a0al (2026) Bispecific T\u2011cell engagers for treatment-refractory autoimmune connective tissue diseases. Nat Med 32:1530\u20131542. https:\/\/doi.org\/10.1038\/s41591-026-04238-4","journal-title":"Nat Med"},{"key":"1846_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau\u00a0P, Garfall\u00a0AL, van de Donk\u00a0NWCJ et\u00a0al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"1846_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","volume":"14","author":"K Nath","year":"2024","unstructured":"Nath\u00a0K, Shekarkhand\u00a0T, Nemirovsky\u00a0D et\u00a0al (2024) Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J 14:88. https:\/\/doi.org\/10.1038\/s41408-024-01043-5","journal-title":"Blood Cancer J"},{"key":"1846_CR33","doi-asserted-by":"crossref","unstructured":"Wilhelm A, et\u00a0al. Selective CAR T\u2011cell-mediated B\u2011cell depletion suppresses IFN signature in SLE. JCI Insight. 2024;9.","DOI":"10.1172\/jci.insight.179433"},{"key":"1846_CR34","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau\u00a0T et\u00a0al (2024) CAR T\u2011cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403:1627\u20131630","journal-title":"Lancet"},{"key":"1846_CR35","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang\u00a0X et\u00a0al (2024) Allogeneic CD19-targeted CAR\u2011T therapy in patients with severe myositis and systemic sclerosis. Cell 187:4890\u20134904.e4899","journal-title":"Cell"},{"key":"1846_CR36","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher\u00a0AC et\u00a0al (2023) CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329:2154\u20132162","journal-title":"JAMA"},{"key":"1846_CR37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ard.2025.06.017","volume":"84","author":"D Khanna","year":"2025","unstructured":"Khanna\u00a0D et\u00a0al (2025) Tolerability and efficacy of BMS-986353 (CC-97540), a CD19-directed CAR T\u2011cell therapy for systemic sclerosis: updated data from the phase 1 BREAKFREE\u20111 study. Ann Rheum Dis 84:841\u2013842","journal-title":"Ann Rheum Dis"},{"key":"1846_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114071","volume":"204","author":"M Subklewe","year":"2024","unstructured":"Subklewe\u00a0M, Magno\u00a0G, Gebhardt\u00a0C, B\u00fccklein\u00a0V, Szelinski\u00a0F, Ar\u00e9valo\u00a0HJR et\u00a0al (2024) Application of blinatumomab, a bispecific anti-CD3\/CD19 T\u2011cell engager, in treating severe systemic sclerosis: a case study. Eur J Cancer 204:114071","journal-title":"Eur J Cancer"},{"key":"1846_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","volume":"83","author":"D Lodka","year":"2024","unstructured":"Lodka\u00a0D et\u00a0al (2024) CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann Rheum Dis 83:499\u2013507","journal-title":"Ann Rheum Dis"},{"key":"1846_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.10.026","author":"AN St\u00fctz","year":"2025","unstructured":"St\u00fctz\u00a0AN, Lahu\u00a0LM, Jaschinski\u00a0S, D\u00fcsing\u00a0C, G\u00fczel\u00a0N, Schwarz\u00a0D et\u00a0al (2025) Mosunetuzumab, a CD20\u00d7CD3 bispecific T\u2011cell engager, in granulomatosis with polyangiitis. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.10.026","journal-title":"Ann Rheum Dis"},{"key":"1846_CR41","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1093\/rheumatology\/keaf077","volume":"64","author":"FN Albach","year":"2025","unstructured":"Albach\u00a0FN et\u00a0al (2025) Targeting autoimmunity with CD19-CAR T\u2011cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology (Oxford) 64:4075\u20134077","journal-title":"Rheumatology (Oxford)"},{"key":"1846_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","volume":"35","author":"Y Li","year":"2025","unstructured":"Li\u00a0Y et\u00a0al (2025) Fourth-generation chimeric antigen receptor T\u2011cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Res 35:220\u2013223","journal-title":"Cell Res"},{"key":"1846_CR43","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci\u00a0L et\u00a0al (2024) Bispecific T\u2011cell engager therapy for refractory rheumatoid arthritis. Nat Med 30:1593\u20131601","journal-title":"Nat Med"},{"key":"1846_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152786","volume":"74","author":"A Nordmann-Gomes","year":"2025","unstructured":"Nordmann-Gomes\u00a0A et\u00a0al (2025) CAR T\u2011cell therapy in SLE: a\u00a0systematic review. Semin Arthritis Rheum 74:152786","journal-title":"Semin Arthritis Rheum"},{"key":"1846_CR45","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1182\/blood.2025028375","volume":"146","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller\u00a0F et\u00a0al (2025) Comparison of the safety profiles of CD19-targeting CAR T\u2011cell therapy in patients with SLE and B\u2011cell lymphoma. Blood 146:1088\u20131095","journal-title":"Blood"},{"key":"1846_CR46","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen\u00a0M et\u00a0al (2025) Local immune effector cell-associated toxicity syndrome in CAR T\u2011cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol 7:e424\u2013e433","journal-title":"Lancet Rheumatol"},{"key":"1846_CR47","unstructured":"Scherlinger M, et\u00a0al. Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a\u00a0case series. Ann Rheum Dis. 2026. PMID: 41792022."}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01846-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01846-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01846-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:20:58Z","timestamp":1785943258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01846-w"}},"subtitle":["Neue T-Zell-basierte Therapien in der Rheumatologie","New T-cell-based treatment in rheumatology"],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1846"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01846-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Pierer und D.\u00a0Simon geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}